Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 9,620,000 shares, a decrease of 46.1% from the June 15th total of 17,840,000 shares. Based on an average trading volume of 1,350,000 shares, the days-to-cover ratio is currently 7.1 days.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $3.97 on Friday. Zentalis Pharmaceuticals has a fifty-two week low of $3.27 and a fifty-two week high of $29.03. The company has a market capitalization of $281.99 million, a price-to-earnings ratio of -1.19 and a beta of 1.70. The firm has a 50-day simple moving average of $8.58 and a 200-day simple moving average of $11.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.91. The business had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same quarter last year, the company posted ($1.07) EPS. Equities research analysts forecast that Zentalis Pharmaceuticals will post -2.72 EPS for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, CFO Cam Gallagher sold 9,597 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Cam Gallagher sold 9,597 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Diana Hausman sold 3,356 shares of the stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the transaction, the insider now directly owns 373,876 shares in the company, valued at approximately $4,718,315.12. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at about $58,000. Opaleye Management Inc. acquired a new stake in Zentalis Pharmaceuticals in the first quarter valued at about $3,152,000. Kennedy Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals in the first quarter valued at about $189,000. Price T Rowe Associates Inc. MD lifted its position in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after purchasing an additional 585,644 shares during the period. Finally, ProShare Advisors LLC lifted its position in Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after purchasing an additional 1,274 shares during the period.

Analyst Ratings Changes

ZNTL has been the topic of several research reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $8.00 price objective (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. HC Wainwright dropped their price objective on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, June 18th. Oppenheimer dropped their price objective on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, June 18th. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $29.00 to $9.00 in a report on Tuesday, June 18th. Finally, Stifel Nicolaus dropped their price objective on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $11.33.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.